| [1] |
|
| [2] |
|
| [3] |
Obrişcǎ B, Jurubiţǎ R, Andronesi A，et al.Histological predictors of renal outcome in lupus nephritis：the importance of tubulointerstitial lesions and scoring of glomerular lesions[J]. Lupus， 2018， 27(9)：1455-1463.DOI： 10.1177/0961203318776109.
|
| [4] |
Singh JA, Hossain A, Kotb A，et al.Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis：a systematic review and network meta-analysis[J]. Syst Rev， 2016， 5(1)：155.DOI： 10.1186/s13643-016-0328-z.
|
| [5] |
Stanley S, Vanarsa K, Soliman S，et al.Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities[J]. Nat Commun， 2020， 11(1)：2197.DOI： 10.1038/s41467-020-15986-3.
|
| [6] |
Birmingham DJ, Merchant M, Waikar SS，et al.Biomarkers of lupus nephritis histology and flare：deciphering the relevant amidst the noise[J]. Nephrol Dial Transplant， 2017， 32(suppl_1)：i71-i79.DOI： 10.1093/ndt/gfw300.
|
| [7] |
Parodis I, Tamirou F, Houssiau FA.Treat-to-target in lupus nephritis.What is the role of the repeat kidney biopsy？[J]. Arch Immunol Ther Exp (Warsz)， 2022， 70(1)：1-8.DOI： 10.1007/s00005-022-00646-9.
|
| [8] |
Hull KL, Adenwalla SF, Topham P，et al.Indications and considerations for kidney biopsy：an overview of clinical considerations for the non-specialist[J]. Clin Med (Lond)， 2022， 22(1)：34-40.DOI： 10.7861/clinmed.2021-0472.
|
| [9] |
Ferragut F, Vachetta VS, Troncoso MF，et al.ALCAM/CD166：a pleiotropic mediator of cell adhesion，stemness and cancer progression[J]. Cytokine Growth Factor Rev， 2021(61)：27-37.DOI： 10.1016/j.cytogfr.2021.07.001.
|
| [10] |
Stanley S, Vanarsa K, Soliman S，et al.Author correction：comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities[J]. Nat Commun， 2020， 11(1)：3131.DOI： 10.1038/s41467-020-16944-9.
|
| [11] |
Lei R, Vu B, Kourentzi K，et al.A novel technology for home monitoring of lupus nephritis that tracks the pathogenic urine biomarker ALCAM[J]. Front Immunol， 2022(13)：1044743.DOI： 10.3389/fimmu.2022.1044743.
|
| [12] |
Chalmers SA, Ayilam Ramachandran R, Garcia SJ，et al.The CD6/ALCAM pathway promotes lupus nephritis via T cell-mediated responses[J]. J Clin Invest， 2022， 132(1).DOI： 10.1172/JCI147334.
|
| [13] |
Ding H, Lin C, Cai J，et al.Urinary activated leukocyte cell adhesion molecule as a novel biomarker of lupus nephritis histology[J]. Arthritis Res Ther， 2020， 22(1)：122.DOI： 10.1186/s13075-020-02209-9.
|
| [14] |
|
| [15] |
Li J, Yu YF, Liu CH, et al. Significance of M2 macrophages in glomerulonephritis with crescents[J]. Pathol Res Pract， 2017， 213(9)：1215-1220.DOI： 10.1016/j.prp.2017.04.011.
|
| [16] |
Huang YJ, Lin CH, Yang HY，et al.Urine soluble CD163 is a promising biomarker for the diagnosis and evaluation of lupus nephritis[J]. Front Immunol， 2022(13)：935700.DOI： 10.3389/fimmu.2022.935700.
|
| [17] |
Zhang T, Li H, Vanarsa K，et al.Association of urine sCD163 with proliferative lupus nephritis，fibrinoid necrosis，cellular crescents and intrarenal M2 macrophages[J]. Front Immunol， 2020(11)：671.DOI： 10.3389/fimmu.2020.00671.
|
| [18] |
Mejia-Vilet JM, Zhang XL, Cruz C，et al.Urinary soluble CD163：a novel noninvasive biomarker of activity for lupus nephritis[J]. J Am Soc Nephrol， 2020， 31(6)：1335-1347.DOI： 10.1681/ASN.2019121285.
|
| [19] |
Parodis I, Gokaraju S, Zickert A，et al.ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus[J]. Rheumatology (Oxford)， 2020， 59(9)：2237-2249.DOI： 10.1093/rheumatology/kez528.
|
| [20] |
Yap D, Kwan L, Ma M，et al.Preemptive immunosuppressive treatment for asymptomatic serological reactivation may reduce renal flares in patients with lupus nephritis：a cohort study[J]. Nephrol Dial Transplant， 2019， 34(3)：467-473.DOI： 10.1093/ndt/gfy024.
|
| [21] |
Yu KY, Yung S, Chau MK，et al.Clinico-pathological associations of serum VCAM-1 and ICAM-1 levels in patients with lupus nephritis[J]. Lupus， 2021， 30(7)：1039-1050.DOI： 10.1177/09612033211004727.
|
| [22] |
Fasano S, Pierro L, Borgia A，et al.Biomarker panels may be superior over single molecules in prediction of renal flares in systemic lupus erythematosus：an exploratory study[J]. Rheumatology (Oxford)， 2020， 59(11)：3193-3200.DOI： 10.1093/rheumatology/keaa074.
|
| [23] |
Liu L, Wang R, Ding H，et al.The utility of urinary biomarker panel in predicting renal pathology and treatment response in Chinese lupus nephritis patients[J]. PLoS One， 2020， 15(10)：e0240942.DOI： 10.1371/journal.pone.0240942.
|
| [24] |
Nagai K, Matsubara T, Mima A，et al.Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy[J]. Kidney Int， 2005， 68(2)：552-561.DOI： 10.1111/j.1523-1755.2005.00433.x.
|
| [25] |
Mok CC, Ding HH, Kharboutli M，et al.Axl，ferritin，insulin-like growth factor binding protein 2，and tumor necrosis factor receptor type II as biomarkers in systemic lupus erythematosus[J]. Arthritis Care Res (Hoboken)， 2016， 68(9)：1303-1309.DOI： 10.1002/acr.22835.
|
| [26] |
Gong S, Xu Z, Liu Y, et al. Plasma sMer, sAxl and GAS6 levels correlate with disease activity and severity in lupus nephritis[J]. Eur J Clin Invest， 2019， 49(3)：e13064.DOI： 10.1111/eci.13064.
|
| [27] |
Parodis I, Ding H, Zickert A，et al.Serum Axl predicts histology-based response to induction therapy and long-term renal outcome in lupus nephritis[J]. PLoS One， 2019， 14(2)：e0212068.DOI： 10.1371/journal.pone.0212068.
|
| [28] |
Farah Izati A, Wong KK, Che Maraina CH.IL-23/IL-17 axis in the pathogenesis and treatment of systemic lupus erythematosus and rheumatoid arthritis[J].Malays J Pathol，2020，42(3)：333-347.
|
| [29] |
Haroon MM, Hegazy GA, Hassanien MA, et al. Significance of interleukin 23 in systemic lupus patients：relation to disease activity and damage indices[J]. Biologics， 2023(17)：1-9.DOI： 10.2147/Btt.S389021.
|
| [30] |
Dedong H, Feiyan Z, Jie S，et al.Analysis of interleukin-17 and interleukin-23 for estimating disease activity and predicting the response to treatment in active lupus nephritis patients[J]. Immunol Lett， 2019(210)：33-39.DOI： 10.1016/j.imlet.2019.04.002.
|
| [31] |
Talaat RM, Mohamed SF, Bassyouni IH，et al.Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients：correlation with disease activity[J]. Cytokine， 2015， 72(2)：146-153.DOI： 10.1016/j.cyto.2014.12.027.
|
| [32] |
Karasu E, Eisenhardt SU, Harant J，et al.Extracellular vesicles：packages sent with complement[J]. Front Immunol， 2018(9)：721.DOI： 10.3389/fimmu.2018.00721.
|
| [33] |
Zhao Y, Wei W, Liu ML.Extracellular vesicles and lupus nephritis-new insights into pathophysiology and clinical implications[J]. J Autoimmun， 2020(115)：102540.DOI： 10.1016/j.jaut.2020.102540.
|
| [34] |
Hinger SA, Cha DJ, Franklin JL，et al.Diverse long RNAs are differentially sorted into extracellular vesicles secreted by colorectal cancer cells[J]. Cell Rep， 2018， 25(3)：715-725.e4.DOI： 10.1016/j.celrep.2018.09.054.
|
| [35] |
Solé C, Cortés-Hernández J, Felip ML，et al.miR-29c in urinary exosomes as predictor of early renal fibrosis in lupus nephritis[J]. Nephrol Dial Transplant， 2015， 30(9)：1488-1496.DOI： 10.1093/ndt/gfv128.
|
| [36] |
Tangtanatakul P, Klinchanhom S, Sodsai P，et al.Down-regulation of let-7a and miR-21 in urine exosomes from lupus nephritis patients during disease flare[J]. Asian Pac J Allergy Immunol， 2019， 37(4)：189-197.DOI： 10.12932/AP-130318-0280.
|
| [37] |
Garcia-Vives E, Solé C, Moliné T, et al. The urinary exosomal miRNA expression profile is predictive of clinical response in lupus nephritis[J]. Int J Mol Sci， 2020， 21(4)：1372.DOI： 10.3390/ijms21041372.
|
| [38] |
Li Y, Xu X, Tang X，et al.MicroRNA expression profile of urinary exosomes in Type IV lupus nephritis complicated by cellular crescent[J]. J Biol Res (Thessalon)， 2018(25)：16.DOI： 10.1186/s40709-018-0088-0.
|
| [39] |
Zheng C, Xie L, Qin H，et al.The role of extracellular vesicles in systemic lupus erythematosus[J]. Front Cell Dev Biol， 2022(10)：835566.DOI： 10.3389/fcell.2022.835566.
|